LigaChem Biosciences, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2006-05-01
- Employees
- 147
- Market Cap
- -
- Website
- http://www.legochembio.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy of Delpazolid As Add-on Therapy in Refractory Mycobacterium Abscessus Complex
- Conditions
- Mycobacterium Abscessus InfectionNontuberculous Mycobacterium Infection
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06004037
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Bundang Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05941507
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
- Conditions
- MRSA Bacteremia
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05225558
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Chosun University Hospital, Gwangju, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches
- Conditions
- Healthy
- Interventions
- Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04939779
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
- Conditions
- Infections and InfestationsPulmonary Tuberculosis
- Interventions
- Drug: Bedaquiline, Delamanid, Moxifloxacin
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT04550832
- Locations
- 🇿🇦
The Aurum Institute Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
🇿🇦Clinical HIV Research Unit (CHRU) University of the Witwatersrand, Johannesburg, South Africa
🇹🇿Ifakara Health Institute, Bagamoyo, Tanzania
- Prev
- 1
- 2
- 3
- Next